TABLE 2

Comparison of susceptibility data for S. maltophilia isolates prior to and after initial treatment

ParameterValue
Prior to initial treatment (n = 98)After initial treatment (n = 21)
No. (%) of susceptible isolates/total
    Trimethoprim-sulfamethoxazolea94/98 (96)15/21 (71)
    Minocycline90/95 (95)12/21 (57)
    Levofloxacinb79/96 (82)6/21 (29)
    Ceftazidime47/95 (49)7/21 (33)
    Ticarcillin-clavulanate38/96 (40)3/21 (14)
Median MIC [μg/ml (IQR)] [n]
    Trimethoprim-sulfamethoxazolec20 (10–320) [91]40 (20–100) [18]
    Minocyclinec1 (0.1–48) [71]3.5 (1–6) [14]
    Levofloxacind1 (0.1–8), [72]8 (3–8) [17]
    Ticarcillin-clavulanated256 (0.4–256) [67]256 (32–256) [15]
    Ceftazidimed24 (1–256) [67]256 (16–256) [15]
  • a Two of 7 (14%) isolates recovered following SXT monotherapy were resistant to SXT, and 2 of 5 (40%) were resistant to levofloxacin.

  • b Ten of 14 (71%) isolates recovered following FQ monotherapy were resistant to levofloxacin, and 0 of 11 (0%) were resistant to SXT.

  • c MIC according to Vitek 2 (bioMérieux).

  • d MIC according to Etest (bioMérieux).